How to buy Sinovac Biotech Ltd shares

Sinovac Biotech Ltd is a biotechnology business with stocks listed in the US. Sinovac Biotech Ltd shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Sinovac Biotech Ltd

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sinovac Biotech Ltd. Find the share by name or ticker symbol: SVA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sinovac Biotech Ltd reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Sinovac Biotech Ltd, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sinovac Biotech Ltd. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

Sinovac Biotech Ltd share price

Use our graph to track the performance of SVA stocks over time.

Sinovac Biotech Ltd shares at a glance

• Key figures

Information last updated 2020-10-18.

52-week range	USD$N/A - USD$N/A
50-day moving average	USD$6.47
200-day moving average	USD$6.47
Target price	USD$6
PE ratio	19.0294
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.282

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Sinovac Biotech Ltd stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sinovac Biotech Ltd by TradingView

Is Sinovac Biotech Ltd under- or over-valued?

Valuing Sinovac Biotech Ltd stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech Ltd's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sinovac Biotech Ltd's P/E ratio

Sinovac Biotech Ltd's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Sinovac Biotech Ltd shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sinovac Biotech Ltd's EBITDA

Sinovac Biotech Ltd's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$59.4 million (£0.0 million).

The EBITDA is a measure of a Sinovac Biotech Ltd's overall financial performance and is widely used to measure a its profitability.

Sinovac Biotech Ltd financials

Revenue TTM	US$224.9 million
Operating margin TTM	24.48%
Gross profit TTM	US$213.6 million
Return on assets TTM	8.44%
Return on equity TTM	16.95%
Profit margin	16.58%
Book value	2.869
Market capitalisation	US$460.2 million

TTM: trailing 12 months

Shorting Sinovac Biotech Ltd shares

There are currently 199,773 Sinovac Biotech Ltd shares held short by investors – that's known as Sinovac Biotech Ltd's "short interest". This figure is 0% down from 199,773 last month.

There are a few different ways that this level of interest in shorting Sinovac Biotech Ltd shares can be evaluated.

Sinovac Biotech Ltd's "short interest ratio" (SIR)

Sinovac Biotech Ltd's "short interest ratio" (SIR) is the quantity of Sinovac Biotech Ltd shares currently shorted divided by the average quantity of Sinovac Biotech Ltd shares traded daily (recently around inf billion). Sinovac Biotech Ltd's SIR currently stands at 0. In other words for every 100,000 Sinovac Biotech Ltd shares traded daily on the market, roughly 0 shares are currently held short.

However Sinovac Biotech Ltd's short interest can also be evaluated against the total number of Sinovac Biotech Ltd shares, or, against the total number of tradable Sinovac Biotech Ltd shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sinovac Biotech Ltd's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sinovac Biotech Ltd shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Sinovac Biotech Ltd shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sinovac Biotech Ltd.

Find out more about how you can short Sinovac Biotech Ltd stock.

Sinovac Biotech Ltd share dividends

We're not expecting Sinovac Biotech Ltd to pay a dividend over the next 12 months.

Sinovac Biotech Ltd share price volatility

Over the last 12 months, Sinovac Biotech Ltd's shares have ranged in value from as little as US$N/A up to US$N/A. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sinovac Biotech Ltd's is 0.102. This would suggest that Sinovac Biotech Ltd's shares are less volatile than average (for this exchange).

Sinovac Biotech Ltd overview

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.

Frequently asked questions

• What percentage of Sinovac Biotech Ltd is owned by insiders or institutions?

  Currently 15.887% of Sinovac Biotech Ltd shares are held by insiders and 23.11% by institutions.

• When does the fiscal year end for Sinovac Biotech Ltd?

  Sinovac Biotech Ltd's fiscal year ends in December.

• Where is Sinovac Biotech Ltd based?

  Sinovac Biotech Ltd's address is: No.39, SHANGDI West Road, Beijing, China, 100085

• What is Sinovac Biotech Ltd's ISIN number?

  Sinovac Biotech Ltd's international securities identification number is: USP8696W1047

• What is Sinovac Biotech Ltd's CUSIP number?

  Sinovac Biotech Ltd's Committee on Uniform Securities Identification Procedures number is: P8696W104